Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company achieved revenue of 1.246 billion RMB in 1H25, a year-on-year decrease of 20.9%, and a net profit attributable to the parent company of 189 million RMB, down 46.8% year-on-year, primarily due to domestic policy changes affecting hospital demand and a weaker outbreak of respiratory infectious diseases compared to the same period in 2024 [1][3] - Despite short-term challenges, the company is expected to maintain long-term growth potential due to its expanding product portfolio and improving domestic and international sales networks [1][3] Summary by Sections Revenue and Profitability - The company's gross margin in 1H25 was 62.9%, a decrease of 1.5 percentage points year-on-year, attributed to domestic policy changes impacting product pricing [2] - The sales, management, and R&D expense ratios for 1H25 were 25.6%, 7.3%, and 14.0%, respectively, with increases of 5.4, 0.5, and 1.5 percentage points year-on-year, indicating ongoing investment in commercialization and R&D [2] Business Segments - The U.S. subsidiary's revenue in 1H25 is estimated to have grown nearly 20%, supported by stable toxicology testing and new respiratory testing products [3] - The international department's revenue is expected to show steady growth due to ongoing localization efforts and the introduction of new products [3] - Domestic business revenue is projected to decline in 1H25 due to external environmental factors, but long-term growth is anticipated through strategic advancements in immunofluorescence and other key areas [3] Long-term Business Outlook - Infectious disease testing revenue was 379 million RMB, down 21.1% year-on-year, primarily due to lower outbreak intensity [4] - Chronic disease testing revenue was 563 million RMB, down 26.1% year-on-year, affected by policy changes [4] - Toxicology and prenatal testing revenues were 145 million RMB and 138 million RMB, showing growth of 4.3% and a decline of 11.7% respectively, with expectations for improvement through new product launches and e-commerce channel development [4] Profit Forecast and Valuation - The report adjusts the profit forecast for 2025-2027, estimating net profits of 426 million RMB, 491 million RMB, and 582 million RMB, reflecting downward adjustments of 35% for 2025 and 2026, and 33% for 2027 [5][13] - The company is valued at a 34x PE for 2025, with a target price of 30.09 RMB, up from a previous estimate of 27.07 RMB [5][8]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 27.07 RMB [7][8]. Core Insights - The company achieved revenue and net profit of 306.5 million RMB and 56.2 million RMB in 2024, representing year-over-year growth of 10.9% and 15.2%, respectively, although these figures fell short of market expectations [1]. - The gross margin for 2024 was 64.2%, an increase of 1.5 percentage points year-over-year, attributed to an optimized product revenue structure [1]. - The operating cash flow for 2024 was 362 million RMB, reflecting a 10.1% year-over-year increase, indicating a positive cash flow trend [1]. Revenue Growth Projections - The international department is expected to see a revenue increase of approximately 30% in 2024, driven by the expansion of immunofluorescence and single-use luminescence businesses [2]. - Domestic business is projected to grow by about 10% in 2024, supported by deeper market penetration in emergency departments and strategic engagement with higher-tier hospitals [2]. - The U.S. subsidiary is anticipated to experience a slight revenue decline in 2024 due to intensified competition in the North American toxicology testing market, but is expected to recover in 2025 with new product contributions [2]. Business Segment Performance - The infectious disease testing segment is projected to generate 1.042 billion RMB in revenue for 2024, with a year-over-year growth of 9.5%, driven by increasing demand for routine testing [3]. - The chronic disease testing segment is expected to achieve 1.369 billion RMB in revenue for 2024, reflecting a robust year-over-year growth of 22.4%, bolstered by steady promotion of immunofluorescence products [3]. - The toxicology and prenatal testing segments are forecasted to generate revenues of 286 million RMB and 294 million RMB, respectively, with the latter expected to grow by 10% year-over-year [3]. Profitability Forecast and Valuation - The report adjusts the company's revenue growth and sales expense rate forecasts, projecting net profits of 652 million RMB, 752 million RMB, and 867 million RMB for 2025-2027, with significant downward adjustments of 23.3% and 30.5% for 2025 and 2026, respectively [4]. - The company is positioned as a leader in the domestic POCT industry, with a diverse product range and ongoing commercialization efforts, warranting a 20x PE for 2025, leading to a target price of 27.07 RMB [4].